Two separate joint ventures never materialized for Greek biotech company Amyndas, leaving it first to ponder why, and later to blame Zealand Pharma and its US affiliate for running away with its secrets.
by mikkel holmgaard winding, translated by daniel pedersen
”When biotech firms engage in the entrepreneurial equivalent of musical chairs, one firm sometimes gets left out in the cold. That is essentially what happened here.”
An HR expert points to increasing competition for skilled workers combined with their pandemic fatigue as factors behind initiatives like Novo Nordisk’s advanced salary talks, Genmab’s extra day off a month, and Bavarian Nordic’s gift of four vacation days.